Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

CAPR vs MESO: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CAPR Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 5–5 Matrix Metrics)

CAPR Overall Winner 6-Pillar Tally: CAPR 3 – 2 MESO (1 Tie) Matrix Metrics: CAPR 5 – 5 MESO

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas MESO carries 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin).

  • Composite vs. Pillar Nuance: While MESO currently prints a higher short-term Unified Composite Score (34.6/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -42.6% operating margin) and revenue trajectory (-7.9% vs. +390.7% YoY).
  • Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both CAPR (28.0/100 SELL) and MESO (34.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About CAPR vs MESO
CAPR NASDAQ Head-to-Head Winner
Capricor Therapeutics Inc
Pharmaceutical Preparations
$8.47
-11.12% 1D
Market Cap $595.4M
TTM Revenue $11M
Forward P/E 78.7x
Beta / 30D Vol 1.52β · 152% Vol
Unified Composite Score
28.0 / 100 SELL
Tech 50.0 Fund 37.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (1.2% over 20 days), RSI 51
RSI-14: 51.3 · SMA20: $7.79 · SMA50: $8.08
MESO NASDAQ
Mesoblast Limited American Depositary Shares
Biological Products, (No Diagnostic Substances)
$12.47
-6.03% 1D
Market Cap $1.7B
TTM Revenue $120M
Forward P/E N/M
Beta / 30D Vol 1.18β · 78% Vol
Unified Composite Score
34.6 / 100 SELL
Tech 25.0 Fund 40.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 39
RSI-14: 39.0 · SMA20: $13.64 · SMA50: $14.22

6-Pillar Scorecard Institutional Category Breakdown (CAPR 3 – 2 MESO)

Columns: Metric · CAPR · MESO
1. Valuation Multiples CAPR
Forward P/E 78.7x N/M
Trailing P/E 78.7x N/M
PEG Ratio 0.38x N/M
EV / Revenue 57.8x 14.1x
2. Growth & Scale MESO
Revenue Growth (YoY) -7.9% +390.7%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $120M
Market Cap $595.4M $1.7B
3. Profitability & Quality CAPR
Gross Margin N/A 80.0%
Operating Margin 0.0% -42.6%
Net Profit Margin 0.0% -47.8%
Return on Equity (ROE) -100.5% -9.9%
4. Balance Sheet & Cash Flow MESO
Cash Generation (TTM) -$146M -$45M EBITDA
Cash Flow Margin N/A -37.1% EBITDA Mgn
Net Cash / Leverage $48M Net Debt (0.44x D/E) $4.38 Book/Sh · -9.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CAPR
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 637.1% (89th %ile) 76.8% (37th %ile)
Put/Call OI Skew 1.57x (Put-Skewed) Thin ADR Chain
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: CAPR (5) vs MESO (5)
Institutional Metric CAPR MESO Criterion Row Edge
Market Capitalization
Scale
$595.4M $1.7B Larger Scale MESO
Trailing P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Forward P/E Ratio
Valuation
78.7x N/M Lower Multiple CAPR
Revenue Growth (YoY)
Growth
-7.9% +390.7% Higher Growth MESO
Operating Margin (TTM)
Profitability
0.0% -42.6% Higher Margin CAPR
Net Profit Margin
Profitability
0.0% -47.8% Higher Margin CAPR
Return on Equity (ROE)
Capital Efficiency
-100.5% -9.9% Higher ROE MESO
52-Week Range Position
Momentum
15% ($3–$40) 6% ($12–$22) Stronger Trend CAPR
Beta / 30D Volatility
Risk Regime
1.52β · 152% Vol 1.18β · 78% Vol Lower Realized Risk MESO
Unified Institutional Score
Composite Signal
28.0 / 100 (SELL) 34.6 / 100 (SELL) Higher Composite MESO
Trailing 12M Revenue (USD)
Operating Scale
$11M $120M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 80.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.38x PEG · 57.8x EV/Rev N/M PEG · 14.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$146M ($48M Net Debt (0.44x D/E)) -$45M EBITDA ($4.38 Book/Sh · -9.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon CAPR +32.33 pp
CAPR: +26.23% · MESO: -6.1%
3M Horizon CAPR +44.82 pp
CAPR: +19.63% · MESO: -25.19%
6M Horizon MESO +53.77 pp
CAPR: -70.58% · MESO: -16.81%
1Y Horizon CAPR +63.21 pp
CAPR: +46.79% · MESO: -16.42%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CAPR vs MESO. Trailing 12-month operating profitability (CAPR 0.0% vs MESO -42.6%) and valuation multiples (CAPR 78.7x vs MESO N/M Forward P/E) are benchmarked directly in Pillar 4 below.

CAPR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$11M
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-100.5% · 78.7x
MESO ADR TTM Benchmark FX-Normalized USD
TTM Revenue$120M
Gross Margin80.0%
Op. Margin-42.6%
ROE / Fwd P/E-9.9% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
CAPR CONSOLIDATION
56d in phase · OBV ACCUMULATION
Current IV 637.1%
IV Percentile 89th %ile
Put/Call OI Skew 1.57x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MESO UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 76.8%
IV Percentile 37th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MESO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
CAPR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $595.4M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
MESO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.7B market capitalization and -42.6% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ CAPR vs MESO Key Questions & Quantitative Answers

As of Nov 16, 2026, Capricor Therapeutics Inc (CAPR) is the stronger overall head-to-head candidate over Mesoblast Limited (MESO) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Options & Positioning). CAPR carries a Unified Composite Score of 28.0/100 (SELL) at $8.47 (78.7x Forward P/E, 0.0% operating margin), whereas MESO carries 34.6/100 (SELL) at $12.47 (N/M Forward P/E, -42.6% operating margin). Composite vs. Pillar Nuance: While MESO currently prints a higher short-term Unified Composite Score (34.6/100 SELL vs. CAPR 28.0/100 SELL), CAPR captures the overall institutional head-to-head verdict (5–5 matrix metrics and 3–2 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -42.6% operating margin) and revenue trajectory (-7.9% vs. +390.7% YoY). Defensive Composite Rating Caution: Although CAPR compares more favorably head-to-head, both CAPR (28.0/100 SELL) and MESO (34.6/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: CAPR trades in a Markup technical trend (CONSOLIDATION options phase, RSI 51.3); meanwhile MESO is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 39.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

MESO leads the Growth & Scale pillar: CAPR posts -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin), compared with MESO at +390.7% YoY revenue growth and +0.0% YoY earnings growth on $120M TTM revenue (80.0% gross margin, -42.6% operating margin). On trailing 12-month operating scale, CAPR generates $11M in USD-normalized revenue versus $120M for MESO. In operating R&D and SG&A reinvestment, CAPR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MESO.

CAPR screens cheaper on headline valuation multiples. CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin), whereas MESO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 14.1x EV/Revenue (-37.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CAPR (-100.5% ROE) versus MESO (-9.9% ROE) capital efficiency.

In options market volatility and institutional positioning, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk). By comparison, MESO carries 76.8% implied volatility (37th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.18β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.